Clinical Trial Publication Can Be Stalled By Outside Forces, PhRMA Says
Executive Summary
Timely disclosure of clinical trial results is not always within the control of the sponsoring drug company, the Pharmaceutical Research & Manufacturers of America says in revised 1guidelines for industry
You may also be interested in...
ClinicalTrials.gov Compliance Will Improve, PhRMA Tells Rep. Waxman
Industry may need several years to come into complete compliance with ClinicalTrials.gov, the Pharmaceutical Research & Manufacturers of America indicated in a letter to Rep. Henry Waxman (D-Calif.)
Rx Industry Research Foundation Proposed By Sloan-Kettering Oncologist
Pharmaceutical companies should establish a collaborative foundation to fund basic scientific research to support oncologic drug development, Memorial Sloan-Kettering Cancer Center Director of Breast Cancer Programs Larry Norton, MD, said
GSK Faces New York Suit Over Paxil: Publish Or Punish?
GlaxoSmithKline's failure to publish pediatric safety study results for its antidepressant Paxil (paroxetine) is one basis of fraud allegations lodged against the company by New York Attorney General Eliot Spitzer